What we're reading, October 28, 2016: Medicare blocks some efforts to automatically move customers eligible for Medicare into Medicare Advantage; the first lung cancer vaccine developed in Cuba will be tested in the US; and American Red Cross and Teladoc partner for disaster relief.
CMS is barring efforts from some health insurance companies to automatically move consumers eligible for Medicare into Medicare Advantage. According to Kaiser Health News, there are 29 insurers that are currently allowed to do seamless conversion to switch a customer from a commercial plan when they become eligible for Medicare at age 65. The problem is the conversion is not clear for some seniors, who first learn they’ve been moved into a new plan when they receive an expensive out-of-network provider bill or learn they’ve been given a new primary care doctor.
A lung cancer vaccine developed in Cuba will be tested in the United States for the first time. The trial at the Roswell Park Cancer Institute in Buffalo, New York, will enroll up to 90 patients and will take 3 years to complete, reported The Washington Post. The vaccine has already been approved in some other countries. The US trial will test the vaccine in combination with the immunotherapy Opdivo to see if pairing the 2 improves effectiveness.
A partnership between the American Red Cross and Teladoc will help deliver medical care to communities affected by natural disasters. The companies announced that the partnership will make Teladoc’s network of physicians available to people helped by Red Cross. The virtual services will make it possible for victims of natural disasters to access health services.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More